Clinical trial
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
NCT05153408
Study timeline
Study start (actual)2022-01-13Date precision: day
Registry last updated2023-06-18
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Lung Neoplasmunresolved
Carcinoma, Non-Small-Cell Lungunresolved
Respiratory Tract Neoplasmsunresolved
Neoplasmsunresolved
Neoplasms by Siteunresolved
Lung Diseasesunresolved
Respiratory Tract Diseasesunresolved
Carcinoma, Bronchogenicunresolved
Bronchial Neoplasmsunresolved
Adenocarcinomaunresolved
Carcinomaunresolved
Neoplasms by Histologic Typeunresolved
Neoplasms, Nerve Tissueunresolved
EGFR C797Sunresolved
EGFR C797Aunresolved
EGFR L858Runresolved
EGFR Exon 19 Deletionunresolved
EGFR Gene Mutationunresolved
EGFR Activating Mutationunresolved
Thoracic Neoplasmsunresolved
Antineoplastic Agentsunresolved
Protein Kinase Inhibitorsunresolved
EGFR C797Gunresolved
EGFR C797Xunresolved
Non Small Cell Lung Cancerunresolved
Interventions
BLU-701DRUG
osimertinibDRUG · verified · RxNorm: osimertinib
carboplatinDRUG · verified · RxNorm: carboplatin
pemetrexedDRUG · verified · RxNorm: pemetrexed
Sponsors & collaborators
Blueprint Medicines Corporationlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05153408 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.